Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CogFer-HF study of intravenous ferric derisomaltose in chronic heart failure with iron deficiency and mild cognitive impairment
2024-515046-17-00Phase 4Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Aug 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric derisomaltose in heart failure (HF) and iron deficiency anemia (IDA) (2 arms), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Change in global cognitive composite score at week 12. Started Aug 2024; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2024-515046-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515046-17-00.